Alpivab approved in EU for uncomplicated influenza in adults and children.- BioCryst Pharma.
BioCryst Pharmaceuticals announced that the European Medicines Agency (EMA) has approved Alpivab (peramivir), a single intravenous (I.V.) infusion for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
The EMA�s approval of Alpivab under the centralized licensing procedure provides marketing authorization for all 28-member states of the European Union, Norway and Iceland. Previously, peramivir injection (RAPIVAB, RAPIACTA, PERAMIFLU) has received approval for commercialization in the United States, Canada, Australia, Japan, Taiwan and Korea.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins